Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 147970
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2002-01-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 147160
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2002-01-15 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 146351
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2002-01-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 145601
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2002-01-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 145284
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2001-12-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

ZITHROMAX

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 147970
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2002-01-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 147160
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2002-01-15 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 146351
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2002-01-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 145601
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2002-01-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 145284
                    [Title] => US FDA Approves Single-Dose Treatment For Pediatric Ear Infections
                    [Summary] => NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media in pediatric patients. 


Azithromycin for oral suspension as a single dose or three-day regimen provides a full course of therapy, while most currently available antibiotics require 10 days of multi-dose treatment. It has unique attributes that include high and sustained drug levels in infected tissues, which make short-course dosing possible. 



                    [DatePublished] => 2001-12-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

abtest

US FDA Approves Single-Dose Treatment For Pediatric Ear Infections

January 22, 2002 - 12:00am

NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of...

Health And Family

US FDA Approves Single-Dose Treatment For Pediatric Ear Infections

January 15, 2002 - 12:00am

NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of...

Health And Family

US FDA Approves Single-Dose Treatment For Pediatric Ear Infections

January 8, 2002 - 12:00am

NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of...

Health And Family

US FDA Approves Single-Dose Treatment For Pediatric Ear Infections

January 1, 2002 - 12:00am

NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of...

Health And Family

US FDA Approves Single-Dose Treatment For Pediatric Ear Infections

December 29, 2001 - 12:00am

NEW YORK -- Pfizer Inc said recently that the U.S. Food and Drug Administration has approved Zithromax (azithromycin for oral suspension) as both a single-dose regimen and a three-day regimen for the treatment of...

Health And Family